Thabe H, Fassbender H G, Laufen H, Gierend M
Z Rheumatol. 1986 Sep-Oct;45(5):271-6.
Serum, synovial fluid and synovial tissue was taken from a total of 25 patients of both sexes on whom a synovectomy had been performed, after a 1, 3, 5, 6 or 7 day treatment with a daily administration of 20 mg Piroxicam (5 patients in each group) and the concentration of Piroxicam (Felden) determined. Parallel to this a part of the synovial tissue taken was histologically examined and classified. The analytical results presented here show that in the mean appr. 33% of the Piroxicam passed from the serum into the synovia, appr. 26% into the non or partially florid synovial tissue and appr. 32% into the florid or highly florid synovial tissue. Felden 20 (Piroxicam) thus fulfills the requirement of a good acting, non-steroidal, antiinflammatory substance (NSAID), namely of being available at the location of the inflammatory process.
从总共25名接受滑膜切除术的患者(男女均有)身上采集血清、滑液和滑膜组织。这些患者每日服用20毫克吡罗昔康,分别接受1、3、5、6或7天的治疗(每组5名患者),然后测定吡罗昔康(费啶)的浓度。与此同时,对采集的部分滑膜组织进行组织学检查并分类。此处给出的分析结果表明,平均约33%的吡罗昔康从血清进入滑膜,约26%进入无炎症或部分有炎症的滑膜组织,约32%进入有炎症或高度有炎症的滑膜组织。因此,费啶20(吡罗昔康)满足了一种良好的、非甾体类抗炎物质(NSAID)的要求,即在炎症过程发生部位可发挥作用。